CN106471373B - 用于治疗、诊断和预后血液系统恶性肿瘤的方法 - Google Patents

用于治疗、诊断和预后血液系统恶性肿瘤的方法 Download PDF

Info

Publication number
CN106471373B
CN106471373B CN201580033662.1A CN201580033662A CN106471373B CN 106471373 B CN106471373 B CN 106471373B CN 201580033662 A CN201580033662 A CN 201580033662A CN 106471373 B CN106471373 B CN 106471373B
Authority
CN
China
Prior art keywords
htr
type
cells
aml
malignancy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580033662.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN106471373A (zh
Inventor
R·穆尼奥斯里苏埃尼奥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Joseph Carreras Institute Of Leukemia
Original Assignee
Joseph Carreras Institute Of Leukemia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joseph Carreras Institute Of Leukemia filed Critical Joseph Carreras Institute Of Leukemia
Publication of CN106471373A publication Critical patent/CN106471373A/zh
Application granted granted Critical
Publication of CN106471373B publication Critical patent/CN106471373B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201580033662.1A 2014-06-27 2015-06-26 用于治疗、诊断和预后血液系统恶性肿瘤的方法 Active CN106471373B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14382249.2 2014-06-27
EP14382249.2A EP2959904A1 (en) 2014-06-27 2014-06-27 Methods for treating, diagnosing and prognosing a haematological malignancy
PCT/EP2015/064571 WO2015197839A1 (en) 2014-06-27 2015-06-26 Methods for treating, diagnosing and prognosing a haematological malignancy

Publications (2)

Publication Number Publication Date
CN106471373A CN106471373A (zh) 2017-03-01
CN106471373B true CN106471373B (zh) 2019-08-23

Family

ID=51162662

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580033662.1A Active CN106471373B (zh) 2014-06-27 2015-06-26 用于治疗、诊断和预后血液系统恶性肿瘤的方法

Country Status (15)

Country Link
US (4) US10195207B2 (cg-RX-API-DMAC7.html)
EP (2) EP2959904A1 (cg-RX-API-DMAC7.html)
JP (2) JP2017526629A (cg-RX-API-DMAC7.html)
KR (1) KR102628235B1 (cg-RX-API-DMAC7.html)
CN (1) CN106471373B (cg-RX-API-DMAC7.html)
AU (2) AU2015279105B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016029562B1 (cg-RX-API-DMAC7.html)
CA (1) CA2953272C (cg-RX-API-DMAC7.html)
DK (1) DK3160472T3 (cg-RX-API-DMAC7.html)
ES (1) ES2796056T3 (cg-RX-API-DMAC7.html)
IL (1) IL249579B (cg-RX-API-DMAC7.html)
MX (1) MX362049B (cg-RX-API-DMAC7.html)
RU (1) RU2727418C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015197839A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201700080B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018022823A1 (en) * 2016-07-28 2018-02-01 Asieris Pharmaceutical Technologies Co., Ltd. Uses of dopamine beta-hydroxylase (dbh) inhibitors and serotonin receptor (5-ht) antagonists for the treatment of cancer
EP3348266A1 (en) * 2017-01-16 2018-07-18 Leukos Biotech, S.L. Combination therapy for treating cancer
JP7002245B2 (ja) * 2017-08-10 2022-01-20 シスメックス株式会社 血液分析装置、血液分析方法およびプログラム
SG11202003886TA (en) * 2017-11-01 2020-05-28 Nat Univ Singapore Use of serotonergic drugs to treat virus-induced thrombocytopenia
BR112020014598A2 (pt) 2018-01-18 2020-12-08 Leukos Biotech, S. L. Forma cristalina de partículas sólidas cocristalinas de apomorfina·ácido palmítico
US11034751B1 (en) 2018-01-30 2021-06-15 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating cancer using serotonin receptor inhibitors
CN111257558B (zh) * 2020-01-19 2021-08-24 江苏省人民医院(南京医科大学第一附属医院) 基于机器学习的慢性淋巴细胞白血病肿瘤细胞识别方法
WO2026092665A1 (en) * 2024-10-31 2026-05-07 Alar Pharmaceuticals Inc. Apomorphine salts, their formulations and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155669A (en) 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 2, 4, 8-triaza-spiro (4, 5) dec-2-enes
US3155670A (en) 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes
NL300886A (cg-RX-API-DMAC7.html) 1962-11-23
US3471515A (en) 1965-02-01 1969-10-07 Sandoz Ag (2-hydroxy-3-substituted aminopropoxy)indoles
US3466325A (en) 1965-04-30 1969-09-09 Haessle Ab 1-(ortho-alkenyl phenoxy) - 2-hydroxy-3-isopropylaminopropanes and the salts thereof
DE1668055B2 (de) 1967-03-10 1973-09-06 Farbwerke Hoechst AG, vormals Mei ster Lucius & Bruning, 6000 Frankfurt Basisch substituierte cyclopentylphenolaether, deren salze mit physiologisch vertraeglichen saeuren und verfahren zu deren herstellung
GB1308191A (en) 1970-04-06 1973-02-21 Science Union & Cie Thiochroman derivatives and a process for preparing them
CA2134038C (en) 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
GB0202337D0 (en) * 2002-02-01 2002-03-20 Univ Birmingham Cancer treatment
KR20040055311A (ko) * 2002-12-20 2004-06-26 주식회사 피앤아이 컨설팅 악성혈액종양 진단용 칩 및 이를 이용한 예후판단 시스템
US20060234240A1 (en) * 2003-02-17 2006-10-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine 1f receptor (5-ht1f)
WO2008098351A1 (en) * 2007-02-14 2008-08-21 University Health Network Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies
WO2008146101A1 (en) * 2007-06-01 2008-12-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Ligands of hvem for treating hematologic malignancies and autoimmune diseases
KR101304150B1 (ko) * 2008-03-04 2013-09-05 라브리스 바이올로직스 인코포레이티드 만성 통증의 치료 방법
RU2636614C2 (ru) * 2009-05-19 2017-11-24 Вивия Байотек С.Л. Способы персонализированного медицинского тестирования ex vivo на гематологические новообразования
WO2015079439A1 (en) * 2013-11-26 2015-06-04 Technion Research And Development Foundation Limited Neuronal modulation
US20150197839A1 (en) * 2014-01-13 2015-07-16 Maria Celeste Rellamas Tria Forming conductive pattern using titania sol-gel

Also Published As

Publication number Publication date
IL249579A0 (en) 2017-02-28
EP2959904A1 (en) 2015-12-30
CA2953272A1 (en) 2015-12-30
RU2016147748A (ru) 2018-08-03
MX2016016994A (es) 2017-06-09
BR112016029562B1 (pt) 2021-07-06
US20220323456A1 (en) 2022-10-13
MX362049B (es) 2019-01-04
JP6846551B2 (ja) 2021-03-24
EP3160472B1 (en) 2020-03-11
US10195207B2 (en) 2019-02-05
ES2796056T3 (es) 2020-11-25
KR102628235B1 (ko) 2024-01-22
RU2727418C2 (ru) 2020-07-21
JP2017526629A (ja) 2017-09-14
WO2015197839A1 (en) 2015-12-30
EP3160472A1 (en) 2017-05-03
US11337984B2 (en) 2022-05-24
IL249579B (en) 2019-03-31
RU2016147748A3 (cg-RX-API-DMAC7.html) 2019-02-13
ZA201700080B (en) 2019-04-24
JP2020097608A (ja) 2020-06-25
DK3160472T3 (da) 2020-06-02
KR20170021253A (ko) 2017-02-27
CN106471373A (zh) 2017-03-01
US20210228593A1 (en) 2021-07-29
AU2020200010B2 (en) 2020-11-19
US20190343843A1 (en) 2019-11-14
BR112016029562A2 (pt) 2017-08-22
AU2015279105B2 (en) 2019-10-03
US20170143735A1 (en) 2017-05-25
AU2015279105A1 (en) 2016-12-15
CA2953272C (en) 2022-10-04
AU2020200010A1 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
US20220323456A1 (en) Methods for treating, diagnosing and prognosing a haematological malignancy
CN104634972B (zh) 抗cxcr1组合物和方法
CN107406881B (zh) 用于指导癌症治疗的内容相关的诊断测试
JP2015533084A (ja) 阻害剤に対する応答を予測するためのバイオマーカーおよび方法、ならびにそれらの使用
US20250043270A1 (en) A method of treating acute myeloid leukemia
JP2015504300A (ja) Nae阻害物質に対する応答のバイオマーカー
US20240398831A1 (en) Compositions comprising small molecule regulators of tumor immunity and methods of using same
WO2022159720A2 (en) Methods to quantify rate of clonal expansion and methods for treating clonal hematopoiesis and hematologic malignancies
US10865415B2 (en) Prevention, diagnosis and treatment of cancer overexpressing GPR160
KR101926841B1 (ko) Srf-yap 및 yap 시그니쳐를 이용한 줄기세포특성을 보이는 기저양 유방암 및 삼중 음성 유방암 진단 및 치료방법
CN116676385B (zh) Linc02096在作为预测食管癌免疫治疗效果、预后的标志物及治疗靶点中的应用
JP2025146792A (ja) 白血病の髄外浸潤マーカー
KR20260068765A (ko) 라소폭시펜을 사용한 고형암 치료
WO2024227553A1 (en) Biomarkers for use in cancer treatment and predicting responsiveness to a cancer therapy
US20170100401A1 (en) Treating Cancer With Drug Combinations
Kaul et al. Cancer Satellite Abstracts
HK1206256B (en) Anti-cxcr1 compositions and methods

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant